For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Like glucagon, multiple factors similarly regulate ... Scientists are especially intrigued by the GPCR family of receptors because, although ~1000 GPCRs have been identified, the function of ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

More recent research has shown that the kidneys also bear glucagon receptors, but besides stimulating production of a minor amount of glucose, their role has been unclear, Dr. Scherer explained.

Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

glucagon-like peptide-1 (GLP-1), and glucagon receptors — experienced the greatest weight loss reductions among the agents studied. Data derived from; Moiz A, et al. Ann Intern Med. 2024 ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...